Molecular Oncology Laboratories, Section of Medical Oncology, Department of Oncology, Weatherall Institute of Molecular Medicine, University of Oxford, UK.
Biochem Pharmacol. 2011 May 15;81(10):1183-91. doi: 10.1016/j.bcp.2011.02.016. Epub 2011 Mar 4.
Angiogenesis has emerged as a critical process for tumour progression. Identifying key pathways involved in the regulation and promotion of angiogenesis has resulted in the development of numerous approaches targeting pro-angiogenic signalling pathways. The most prominent and characterised pro-angiogenic pathway is the vascular endothelial growth factor signalling pathway. This review will describe several inhibitors of angiogenesis currently in clinical trial and their various targets. Targeting pro-angiogenic pathways has improved outcome for many patients, however, the emerging problems with drug resistance with clinically approved angiogenic inhibitors will also be discussed in this review. It is hoped that identifying the causes of tumour re-growth and disease progression following treatment will enable future anti-angiogenic therapies to circumvent resistance.
血管生成已成为肿瘤进展的关键过程。确定参与血管生成调控和促进的关键途径，已经产生了许多针对促血管生成信号通路的方法。最突出和特征性的促血管生成途径是血管内皮生长因子信号通路。本综述将描述目前正在临床试验中的几种血管生成抑制剂及其各种靶点。针对促血管生成途径已经改善了许多患者的预后，然而，与临床批准的血管生成抑制剂相关的耐药性问题也将在本综述中讨论。希望确定治疗后肿瘤复发和疾病进展的原因，将使未来的抗血管生成治疗能够规避耐药性。
